Cardiovascular Health

The researchers found that the effect of ACE inhibitors does not appreciably affect the levels of ACE2 enough to support any changes in the clinical use of these medications.

The new findings suggest that screening and proper management of prediabetes may help to prevent CVD in otherwise healthy individuals, or primary prevention, as well as those with existing heart problems, or secondary prevention, according to the study.

An increasing amount of evidence points to the possibility of COVID-19 causing cardiovascular-neurological dysfunction.

Angiotensin peptides are short proteins that regulate the cardiovascular system and are altered in patients with heart failure and those with COVID-19, according to the press release.

Poor cardiorespiratory fitness can lead to premature death and high blood pressure.

Exercise found to reduce the risk of high blood pressure even in polluted areas.

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study has played a key role in helping the health care industry look closer at the disproportionate risk of comorbidities, such as chronic liver and kidney disease, physical function impairment and frailty, premature reproductive aging, and cancer in patients with HIV.

Investigators have found that shear stress caused by aortic valve stenosis activates white blood cells, leading to potentially harmful inflammation, which in turn accelerates heart disease.

Leung added that this is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on colorectal cancer development, based on a large group of patients who were colorectal cancer-free at the beginning of the study.

Significant morbidity and mortality are associated with an aging population due to cardiovascular disease, which is very common in HIV-infected persons.

Elderly, critically ill COVID-19 patients on lopinavir and ritonavir show an increased risk of bradycardia

Critically ill patients admitted to the intensive care unit (ICU) with coronavirus disease 2019 (COVID-19) are 10 times more likely to develop cardiac arrhythmias.

A recent study showed that long-term exposure to fine particulate outdoor air pollution is a key contributor to cardiovascular disease and death throughout the world, regardless of the income bracket of the various countries.

Collaboration between pharmacists and general practice teams improves patient care and increases savings.

A new heart valve combines the biocompatibility of a biological valve with the robustness of a mechanical one.

COVID-19 attacks the cardiovascular system and may exasperate preexisting heart conditions.

Current research has already found that CVD is among the most common pre-existing conditions among people who die from COVID-19.

Organ transplants from seropositive donors carry a high risk of infection from the transplanted organ.

The paper is an update to previous guidelines released by ACSM and the American Heart Association in 1998.

Data from a new analysis reinforces concerns surrounding the detrimental impact the novel osteoporotic therapy romosozumab can have on cardiovascular health.

Research shows that the over-prescribing of opioids for short term pain management is a widespread issue in the United States.

individuals with four or more depressive symptoms had a 20% increase in cardiovascular events and death.

Current treatment guidelines do not recommend the use of either drug in hospitalized patients with COVID-19 outside of clinical trials.

Reducing salt intake to a healthier level appears to be beneficial for the gut microbiome and blood pressure, especially in females with untreated hypertension, according to researchers at the Medical College of Georgia at Augusta University.

There has been more attention been paid to the pulmonary complications of COVID-19, with less attention being paid to the cardiovascular complications that can result in death or impairment.

This marks the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy in patients with a high cardiovascular risk but without a history of heart attack or stroke.

The work and expertise of a drug utilization pharmacist should be empowered and integrated earlier into a recall process.

Nearly 30% of the 2773 patients with COVID-19 received systemic coagulation during their time in the hospital.

The statement is one of the first from the AHA to focus on providing evidence-based strategies for parents and caregivers to create a healthy food environment for young children.

Evolocumab, when used with diet, can be used as monotherapy or in combination with other lipid-lowering agents for the prevention of cardiovascular events.